Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

New 48-week data from the Phase IIIb APEX trial (NCT04882098) show Tremfya (guselkumab; Johnson & Johnson) produces sustained inhibition of radiographic progression and improved clinical symptoms in ...

Clinicians have traditionally been wary about prescribing multiple targeted therapies for rheumatologic conditions for fear of increasing risk of infection. This study examined a large insurance ...

Advancements in drug development, rising disease awareness, and enhanced diagnostics are driving the psoriatic arthritis treatment market. Key opportunities lie in biologic and targeted therapies, ...

The results send a ‘clear, pragmatic message’ of IL-17 inhibition’s greater potency over IL-12/23 inhibition, an expert says.

People with psoriatic arthritis (PsA) often take medicines to help manage their condition and improve their symptoms. Some of these medicines work directly on the body's immune system and help to ...

Plaque psoriasis drug deucravacitinib (Sotyktu) now looks likely to win a psoriatic arthritis (PsA) indication in the near future, with results after 1 year reported here from one of its key phase III ...

In November 2025, Johnson & Johnson announced several major product developments, including new FDA approvals for DARZALEX ...

If you have psoriatic arthritis, carrying around excess weight can stress your joints. Here's how to lose weight and improve joint health.

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Guselkumab (Tremfya; Johnson & Johnson) continued to reduce signs and symptoms of active psoriatic arthritis (PsA) and ...